Alliance Global Partners analyst Ben Haynor initiated coverage of HeartBeam with a Buy rating and $10 price target. The company has developed methods of capturing/recreating and analyzing vectorcardiograms to aid in identifying true ischemic events, Haynor tells investors in a research note. HeartBeam’s AIMIGo is a credit-card size device that can capture a VCG in 30 seconds when placed on the user’s chest, send the results to HeartBeam’s cloud for interpretation, create a synthesized 12-lead ECG for review, and provide videoconferencing with a telehealth specialist through a connected smartphone application, says the analyst. Haynor expects AIMIGo to generate "almost software-like margins" of 80%.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BEAT: